Double-stranded synthetic oligonucleotides useful for inducing apoptosis of osteoclasts for the treatment of osteopenic pathologies
US7659258B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 30, 2006 |
| Grant date | Feb 9, 2010 |
| Priority date | — |
| Expiry date | Aug 7, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a synthetic double-stranded oligonucleotide capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene. Pharmaceutical compositions comprising the oligonucleotide according to the invention are also described, as well as therapeutic applications of that oligonucleotide, in particular for the treatment of osteopenic diseases such as for example osteoporosis. The oligonucleotide according to the invention is characterized in that it comprises the sequence 5′-ATTTATTTTCAATACTGACT-3′ (SEQ ID NO: 1) or a fragment or a mutant thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.